HC Wainwright Forecasts AC Immune FY2026 Earnings

Key Points

• HC Wainwright forecasts AC Immune will lose $0.54 per share in FY2026, matching the current consensus estimate, and maintains a “Strong Buy” rating. The firm projects a return to profitability in 2027, with EPS rising to $1.73 by 2030.
• AC Immune’s latest quarterly results beat expectations: its $0.16-per-share loss was narrower than the $0.18 consensus loss, while revenue of $3.88 million exceeded the $1.62 million estimate.
• Analyst opinions are mixed, but MarketBeat’s consensus rating is “Moderate Buy” with an average price target of $7.50; shares recently opened at $2.23.

AC Immune (NASDAQ:ACIU - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings estimates for AC Immune in a research report issued on Thursday, November 5th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.54) for the year. HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for AC Immune's Q4 2026 earnings at ($0.23) EPS, FY2027 earnings at $0.43 EPS, FY2028 earnings at $1.15 EPS, FY2029 earnings at $1.65 EPS and FY2030 earnings at $1.73 EPS.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. AC Immune had a negative net margin of 181.38% and a negative return on equity of 105.25%. The business had revenue of $3.88 million during the quarter, compared to the consensus estimate of $1.62 million.

ACIU has been the topic of a number of other research reports. Zacks Research lowered AC Immune from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 28th. BTIG Research reiterated a "buy" rating and set a $8.00 price target on shares of AC Immune in a report on Wednesday, September 23rd. Finally, Weiss Ratings raised AC Immune from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, AC Immune presently has a consensus rating of "Moderate Buy" and an average price target of $7.50.

AC Immune Stock Performance

AC Immune stock opened at $2.23 on Monday. AC Immune has a 52 week low of $2.02 and a 52 week high of $3.90. The firm has a market capitalization of $226.95 million, a PE ratio of -4.46 and a beta of 1.64. The business's 50-day simple moving average is $2.54 and its 200-day simple moving average is $2.70.

Hedge Funds Weigh In On AC Immune

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership raised its holdings in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company's stock valued at $1,116,000 after acquiring an additional 30,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company's stock worth $1,071,000 after acquiring an additional 176,701 shares during the period. Finally, AXQ Capital LP bought a new stake in shares of AC Immune in the 2nd quarter worth approximately $25,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer's disease, Parkinson's disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company's technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.